Affordable Access

deepdyve-link deepdyve-link
Publisher Website

A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50 mg oral dose of the γ-secretase inhibitor avagacestat.

Authors
Type
Published Article
Journal
British Journal of Clinical Pharmacology
1365-2125
Publisher
Wiley Blackwell (Blackwell Publishing)
Publication Date
Volume
75
Issue
1
Pages
136–145
Identifiers
DOI: 10.1111/j.1365-2125.2012.04339.x
PMID: 22616739
Source
Medline
License
Unknown

Abstract

The favourable safety profile and pharmacokinetic effects of avagacestat in this study support its continued development, especially in the target population of elderly subjects with mild cognitive impairment or Alzheimer's disease.

Statistics

Seen <100 times